- Home
- RNG vs ADPT Comparison
RNG vs ADPT Comparison
Compare RNG & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNG | ADPT |
|---|---|---|
| Founded | 1999 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.5B |
| IPO Year | 2013 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RNG | ADPT |
|---|---|---|
| Price | $25.75 | $17.84 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 10 |
| Target Price | ★ $31.14 | $16.60 |
| AVG Volume (30 Days) | 1.1M | ★ 2.1M |
| Earning Date | 02-19-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $2,485,621,000.00 | $252,754,000.00 |
| Revenue This Year | $5.73 | $50.86 |
| Revenue Next Year | $4.37 | $0.53 |
| P/E Ratio | $186.71 | ★ N/A |
| Revenue Growth | 5.45 | ★ 42.57 |
| 52 Week Low | $20.59 | $6.26 |
| 52 Week High | $36.43 | $20.76 |
Technical Indicators
Market Signals| Indicator | RNG | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 31.03 | 58.25 |
| Support Level | $28.14 | $15.45 |
| Resistance Level | $30.03 | $18.39 |
| Average True Range (ATR) | 1.18 | 0.92 |
| MACD | -0.37 | 0.15 |
| Stochastic Oscillator | 3.35 | 79.62 |
Price Performance
Historical ComparisonAbout RNG RingCentral Inc.
RingCentral is a unified communications as a service, or UCaaS, provider. Its software helps users communicate and collaborate via voice, video, and messaging across all device types and all from one platform. RingCentral helps customers modernize and move from legacy on-premises systems to modern, cloud-based systems. Beyond its core RingCentral MVP solution, RingCentral also offers a cloud-based contact center solution, a stand-alone video meetings solution, and webinars.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).